Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
ARK5 inhibitor
DRUG CLASS:
ARK5 inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
HX301 (2)
HX301 (2)
›
Associations
(2)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies (NCT05705505)
Phase 1/2
Onconova Therapeutics, Inc.
Onconova Therapeutics, Inc.
Recruiting
Phase 1/2
Onconova Therapeutics, Inc.
Recruiting
Last update posted :
12/12/2023
Initiation :
03/29/2023
Primary completion :
01/01/2026
Completion :
02/01/2026
PGR
|
MSI-H/dMMR
|
letrozole • narazaciclib (HX301)
The Tolerability and Pharmacokinetics of HX301 Monolactate Capsules in Patients With Advanced Solid Tumors (NCT05731934)
Phase 1
Hangzhou Hanx Biopharmaceuticals, Ltd.
Hangzhou Hanx Biopharmaceuticals, Ltd.
Active, not recruiting
Phase 1
Hangzhou Hanx Biopharmaceuticals, Ltd.
Active, not recruiting
Last update posted :
09/22/2023
Initiation :
09/15/2020
Primary completion :
12/30/2023
Completion :
03/28/2024
PD-L1
|
narazaciclib (HX301)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login